|Bid||142.15 x 200|
|Ask||144.00 x 300|
|Day's Range||142.21 - 143.43|
|52 Week Range||110.76 - 144.35|
|PE Ratio (TTM)||24.85|
|Earnings Date||Jan 23, 2018|
|Forward Dividend & Yield||3.36 (2.40%)|
|1y Target Est||146.82|
The U.S. Food and Drug Administration approved Pfizer Inc's second biosimilar to Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, the company said on Wednesday. Pfizer's Ixifi was approved for all eligible indications of Remicade, including the treatment of bowel disease Crohn's disease and skin disorder plaque psoriasis, the drugmaker said. With the approval, Ixifi joins the ranks of other biosimilars that have claimed market share from Remicade, including Pfizer and Celltrion Inc's Inflectra launched in late 2016, and Renflexis, made by Merck & Co and South Korea's Samsung Bioepis Co Ltd.
Pacer, the exchange traded funds issuer behind a unique suite of trend-following funds, added to its lineup Tuesday with the debut of the Pacer WealthShield ETF (CBOE: PWS). The new ETF tracks the Pacer ...
A next-generation cancer treatment could significantly change multiple myeloma outcomes for thousands of people, generating hundreds of millions of dollars in sales for the company.
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.
Regeneron (REGN) announced that the FDA has accepted for review the company's supplemental Biologics License Application (sBLA) for Eylea with an action date of Aug 11, 2018.
The latest on developments in financial markets (All times local): 4 p.m. Big-company stocks notched gains on Wall Street, bringing more records for major indexes, but smaller companies lagged behind. ...
Now could be the perfect time to add to your portfolio healthcare stocks that can benefit from aging baby boomers and regulatory approvals.
Motus GI Holdings, Inc., , a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that it has appointed Gary J. Pruden to its Board of Directors. Mr. Pruden ...
Lilly's (LLY) gastric cancer drug, Cyramza, meets primary endpoint of progression free survival in a phase III study in first-line advanced gastric cancer patients. However, it failed to improve overall survival.
Johnson & Johnson and Bayer were recently ordered by a Philadelphia court to pay $28 million in damages to an Indiana couple, related to internal bleeding about which the companies did not sufficiently warn patients.
Sanofi (SNY) starts two new phase III studies evaluating isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer.
FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.
Roche (RHHBY) announced interim results from the phase III IMpower150 study of Tecentriq and Avastin plus chemotherapy in people with advanced form of lung cancer.
The stakes are high as Johnson & Johnson seeks an appeals-court ruling tossing out a $151 million judgment over its Pinnacle artificial hips in a case that could foreshadow the outcome for thousands of ...
Dec.13 -- Corrine Png, founder and chief executive officer at Crucial Perspective, discusses her outlook for Asia's airline industry in 2018. She speaks on "Bloomberg Markets: Asia."